101
|
Anderson RC, Bermingham EN, McNabb WC, Cookson AL, Tavendale MH, Armstrong KM, Knowles SO, Roy NC. Moderate levels of dietary sheep milk powder reduce experimentally induced colonic inflammation in rats. ANIMAL PRODUCTION SCIENCE 2010. [DOI: 10.1071/an10015] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
Anecdotal evidence suggests that sheep milk may be more beneficial than cow milk for people with intestinal health problems; however, there are no published reports on the effects of sheep milk on intestinal function. Our hypothesis was that sheep milk powder can reduce the severity of colonic inflammation in rats with dextran sodium sulfate (DSS)-induced colitis. A preliminary experiment investigated the palatability of sheep milk powder in the diet of 5-week-old rats with (n = 8) or without (n = 8) DSS-induced colitis. Increasing sheep milk powder from 11 to 56% in the diet had no effect (P > 0.05) on food intake, showing that rats readily eat low and high levels of sheep milk powder in the diet, with or without DSS. Experiment 2 investigated the effects of moderate levels of sheep milk powder (11%) in rat diet on colon morphology, colonic biochemical markers of intestinal function, and caecal short-chain fatty acid concentrations, with (n = 8) or without (n = 8) DSS-induced colitis. Colon total histological injury scores decreased and caecal concentrations of butyric and propionic acids were increased (P < 0.05) in DSS rats fed moderate (11%) dietary levels of sheep milk powder. Experiment 3 investigated the effects of high levels (56%) of sheep milk powder in rat diet on colonic markers of intestinal inflammation, and caecal microbial populations, with (n = 11) or without (n = 8) DSS-induced colitis. Sheep milk powder at 56% of the diet had no effect on colonic biochemical markers of intestinal health, or on caecal short-chain fatty acid concentrations. However, the caecal digesta concentrations of beneficial microbial populations (lactobacilli, bifidobacteria and clostridia) were increased (P < 0.05) and the concentrations of potentially harmful bacteria (coliforms) were decreased (P < 0.05). These results suggest the benefits of moderate levels of sheep milk during DSS-induced colonic inflammation may be due to alterations in the caecal microbiota composition, and further investigation into its health benefits are warranted.
Collapse
|
102
|
Post-weaning effects of milk and milk components on the intestinal mucosa in inflammation. Mutat Res 2009; 690:64-70. [PMID: 20036674 DOI: 10.1016/j.mrfmmm.2009.12.006] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2009] [Revised: 12/14/2009] [Accepted: 12/15/2009] [Indexed: 12/16/2022]
Abstract
Many milk-derived components have immunomodulatory and anti-inflammatory properties, and some of these reduce intestinal inflammation when orally administered to animal models of colitis. However, the potential for ruminant milk or milk components to benefit people with intestinal inflammatory disorders (such as Inflammatory Bowel Disease) has not been well-researched. This review describes published research into mechanisms by which ruminant milk and its components may have beneficial effects when consumed by people who have intestinal inflammation.
Collapse
|
103
|
Bovine colostrum inhibits nuclear factor κB–mediated proinflammatory cytokine expression in intestinal epithelial cells. Nutr Res 2009; 29:275-80. [DOI: 10.1016/j.nutres.2009.03.011] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2009] [Revised: 03/17/2009] [Accepted: 03/26/2009] [Indexed: 11/23/2022]
|
104
|
Abstract
Prebiotics are nondigestible fermentable fibers that are reported to have health benefits for the host. Older as well as more recent studies show beneficial effects in experimental colitis and lately also in human inflammatory bowel diseases (IBD), such as Crohn's disease, ulcerative colitis, and chronic pouchitis. In this review we give an overview of the benefits of prebiotics in rodent IBD models and in IBD patients and discuss their possible protective mechanisms. Commensal intestinal bacteria induce and perpetuate chronic intestinal inflammation, whereas others are protective. However, most of the current medications are directed against the exaggerated proinflammatory immune response of the host, some of them toxic and costly. Feeding prebiotics changes the composition of the intestinal microflora toward more protective intestinal bacteria and alters systemic and mucosal immune responses of the host. Therapy for IBD targeting intestinal bacteria and their function is just emerging. Prebiotics have the promise to be relatively safe, inexpensive, and easy to administer. Unraveling their protective mechanisms will help to develop rational applications of prebiotics. However, the initial promising results with dietary prebiotics in preclinical trials as well as small studies in human IBD will need to be confirmed in large randomized controlled clinical trials.
Collapse
Affiliation(s)
- Mirjam A C Looijer-van Langen
- Centre of Excellence for Gastrointestinal Inflammation and Immunity Research, University of Alberta, Edmonton, Alberta, Canada
| | | |
Collapse
|
105
|
MARTINEZ-FEREZ ANTONIO, GUADIX ANTONIO, ZAPATA-MONTOYA JOSEE, GUADIX EMILIAM. Influence of transmembrane pressure on the separation of caprine milk oligosaccharides from protein by cross-flow ultrafiltration. INT J DAIRY TECHNOL 2008. [DOI: 10.1111/j.1471-0307.2008.00434.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
106
|
Steed H, Macfarlane GT, Macfarlane S. Prebiotics, synbiotics and inflammatory bowel disease. Mol Nutr Food Res 2008; 52:898-905. [PMID: 18383235 DOI: 10.1002/mnfr.200700139] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
The normal colonic microflora is intimately involved in the aetiology of inflammatory bowel diseases (IBD) such as ulcerative colitis (UC) and Crohn's disease (CD). These conditions are often refractile to conventional treatments involving the employment of anti-inflammatory and immunosuppressant drugs, and this has led to a search for alternative therapies based on the use of probiotics, prebiotics and synbiotics. The majority of investigations in this area have been done with probiotics, and while there is increasing interest in the abilities of prebiotics and synbiotics to control the symptoms of IBD, very few randomised controlled trials have been reported. Although the results have been variable, human and animal studies have demonstrated that in many circumstances, these functional foods can alter the composition of the colonic microbiota, reduce inflammatory processes in the gut mucosa, and have the potential to induce disease remission. More work is needed to understand the effects of prebiotics and synbiotics on microbial communities in the gut, and their interactions with the host's immune system.
Collapse
Affiliation(s)
- Helen Steed
- Gut Group, University of Dundee, Ninewells Hospital Medical School, Dundee, UK
| | | | | |
Collapse
|
107
|
Hofseth LJ. Nitric oxide as a target of complementary and alternative medicines to prevent and treat inflammation and cancer. Cancer Lett 2008; 268:10-30. [PMID: 18440130 PMCID: PMC2680023 DOI: 10.1016/j.canlet.2008.03.024] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2008] [Revised: 03/14/2008] [Accepted: 03/19/2008] [Indexed: 02/07/2023]
Abstract
Nitric oxide (NO) and associated reactive nitrogen species (RNS) are involved in many physiological functions. There has been an ongoing debate to whether RNS can inhibit or perpetuate chronic inflammation and associated carcinogenesis. Although the final outcome depends on the genetic make-up of its target, the surrounding microenvironment, the activity and localization of nitric oxide synthase (NOS) isoforms, and overall levels of NO/RNS, evidence is accumulating that in general, RNS drive inflammation and cancers associated with inflammation. To this end, many complementary and alternative medicines (CAMs) that work in chemoprevention associated with chronic inflammation, are inhibitors of excessive NO observed in inflammatory conditions. Here, we review recent literature outlining a role of NO/RNS in chronic inflammation and cancer, and point toward NO as one of several targets for the success of CAMs in treating chronic inflammation and cancer associated with this inflammation.
Collapse
Affiliation(s)
- Lorne J Hofseth
- Department of Pharmaceutical and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, 770 Sumter Street, Coker Life Sciences, Room 513C, Columbia, SC 29208, USA.
| |
Collapse
|
108
|
|
109
|
Macfarlane GT, Steed H, Macfarlane S. Bacterial metabolism and health-related effects of galacto-oligosaccharides and other prebiotics. J Appl Microbiol 2008; 104:305-44. [PMID: 18215222 DOI: 10.1111/j.1365-2672.2007.03520.x] [Citation(s) in RCA: 181] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Most studies involving prebiotic oligosaccharides have been carried out using inulin and its fructo-oligosaccharide (FOS) derivatives, together with various forms of galacto-oligosaccharides (GOS). Although many intestinal bacteria are able to grow on these carbohydrates, most investigations have demonstrated that the growth of bifidobacteria, and to a lesser degree lactobacilli, is particularly favoured. Because of their safety, stability, organoleptic properties, resistance to digestion in the upper bowel and fermentability in the colon, as well as their abilities to promote the growth of beneficial bacteria in the gut, these prebiotics are being increasingly incorporated into the Western diet. Inulin-derived oligosaccharides and GOS are mildly laxative, but can result in flatulence and osmotic diarrhoea if taken in large amounts. However, their effects on large bowel habit are relatively minor. Although the literature dealing with the health significance of prebiotics is not as extensive as that concerning probiotics, considerable evidence has accrued showing that consumption of GOS and FOS can have significant health benefits, particularly in relation to their putative anti-cancer properties, influence on mineral absorption, lipid metabolism, and anti-inflammatory and other immune effects such as atopic disease. In many instances, prebiotics seem to be more effective when used as part of a synbiotic combination.
Collapse
Affiliation(s)
- G T Macfarlane
- Dundee University Gut Group, Ninewells Hospital Medical School, Dundee, UK.
| | | | | |
Collapse
|
110
|
Abstract
Research on human milk oligosaccharides (HMO) began with the characterisation of their chemical structures and is now focused on the elucidation of their biological roles. Previously, biological effects could only be investigated with fractions or structures isolated from breast milk; consequently, clinical observations were limited to comparisons between outcomes from breast-fed infants and their formula-fed counterparts. In some cases, it was inferred that the observed differences were caused by the presence of HMO in breast milk. Presently, analytical techniques allow for the fast analysis of milk samples, thus providing insights on the inherent variability of specimens. In addition, methods for the synthesis of HMO have provided single structures in sufficient quantities to perform clinical studies with oligosaccharide-supplemented formulae. Furthermore, studies have been conducted with non-mammalian oligosaccharides with the purpose of assessing the suitability of these structures to functionally emulate HMO. Taken together, these developments justify summarising current knowledge on HMO to further discussions on efforts to emulate human milk in regard to its oligosaccharide content. The present account summarises published data and intends to provide an historical context and to illustrate the state of the field.
Collapse
|
111
|
Damaskos D, Kolios G. Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'. Br J Clin Pharmacol 2008; 65:453-67. [PMID: 18279467 DOI: 10.1111/j.1365-2125.2008.03096.x] [Citation(s) in RCA: 105] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
The intestinal microflora is a large bacterial community that colonizes the gut, with a metabolic activity equal to an organ and various functions that affect the physiology and pathology of the host's mucosal immune system. Intestinal bacteria are useful in promotion of human health, but certain components of microflora, in genetically susceptible individuals, contribute to various pathological disorders, including inflammatory bowel disease. Clinical and experimental observations indicate an imbalance in protective and harmful microflora components in these disorders. Manipulation of gut flora to enhance its protective and beneficial role represents a promising field of new therapeutic strategies of inflammatory bowel disease. In this review, we discuss the implication of gut flora in the intestinal inflammation that justifies the role of probiotics and prebiotics in the prevention and treatment of inflammatory bowel disease and we address the evidence for therapeutic benefits from their use in experimental models of colitis and clinical trials.
Collapse
Affiliation(s)
- Dimitrios Damaskos
- Second Department of Surgery, General Hospital of Nikea, Piraeus, Greece [corrected]
| | | |
Collapse
|
112
|
Leenen CHM, Dieleman LA. Inulin and oligofructose in chronic inflammatory bowel disease. J Nutr 2007; 137:2572S-2575S. [PMID: 17951505 DOI: 10.1093/jn/137.11.2572s] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Crohn's disease and ulcerative colitis, also called chronic inflammatory bowel diseases (IBD), affect up to 500 per 100,000 persons in the Western world. Recent studies in the etiology of IBD suggest that these diseases are caused by a combination of genetic, environmental, and immunological factors. Results from humans and especially animal models of colitis reported by our group and others have indicated that these diseases result from a lack of tolerance to resident intestinal bacteria in genetically susceptible hosts. Probiotic bacteria have health-promoting effects for the host when ingested and have also shown efficacy in ulcerative colitis and refractory pouchitis. In light of the efficacy of providing probiotic bacteria to patients with IBD, there has been interest in the prophylactic and therapeutic potential of inulin, oligofructose, and other prebiotics for patients with or at risk of IBD. Prebiotics are nondigestible dietary oligosaccharides that affect the host by selectively stimulating growth, activity, or both of selective intestinal (probiotic) bacteria. Prebiotics are easy to administer and, in contrast to probiotic therapy, do not require administration of large amounts of (live) bacteria and are therefore easier to administer. Studies using prebiotics, especially beta-fructan oligosaccharides, for the treatment of chronic intestinal inflammation have shown benefit in animal models of colitis. Studies using these prebiotics alone or in combination with probiotics are emerging and have shown promise. These dietary therapies could lead to novel treatments for these chronic debilitating diseases.
Collapse
Affiliation(s)
- Celine H M Leenen
- Centre of Excellence for Gastrointestinal Inflammation and Immunity Research, University of Alberta, Edmonton, Alberta, Canada
| | | |
Collapse
|
113
|
Abstract
The prokaryotic and eukaryotic cells of the colon exist in a highly complex, but harmonious relationship. Disturbances in this remarkable symbiosis can result in the development of inflammatory bowel diseases (IBD). Although the etiology of IBD is not entirely understood, it is known that the chronic inflammation of Crohn’s disease, ulcerative colitis and chronic pouchitis are a result of an overly aggressive immune response to the commensal intestinal flora in genetically susceptible hosts. Recent studies have enhanced our ability to understand the interaction between the host and its intestinal microflora and the role the microflora plays in maintaining intestinal homeostasis. As we begin to understand the benefits conferred to the intestine by the microflora, the notion of modifying the composition of the bacterial load to improve human health has arisen. A significant body of research now exists investigating the role of probiotics and prebiotics in ameliorating chronic intestinal inflammation. This article will begin with an overview of the role of the commensal microflora in maintaining mucosal immune homeostasis, and how a dysregulated immune response to the intestinal microflora results in IBD. This will be followed by a summary of the use of probiotics and prebiotics in experimental and human IBD.
Collapse
Affiliation(s)
- Julia B Ewaschuk
- Centre for Excellence for Gastrointestinal Inflammation and Immunity Research, University of Alberta, Edmonton, Alberta, T6G 2X8, Canada
| | | |
Collapse
|